Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.
While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.
Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.
GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.
Pharmaceuticals are entering a transition into a far more complex era of patient therapies, and patient segmentation.
Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.
It has been a long wait, but for Alzheimer’s at least, this is the beginning of renewed hope.
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
A proposed database includes key information about critical drugs, such as the country of origin and quantity, so supply chain weaknesses can be identified.
The debate surrounding drug pricing changes rages on.